{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:11:54Z","timestamp":1770509514038,"version":"3.49.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1097\/ftd.0b013e3181fd4c30","type":"journal-article","created":{"date-parts":[[2010,11,13]],"date-time":"2010-11-13T09:18:30Z","timestamp":1289639910000},"page":"128-131","source":"Crossref","is-referenced-by-count":17,"title":["Abbott ARCHITECT Clinical Chemistry and Immunoassay Systems: Digoxin Assays Are Free of Interferences From Spironolactone, Potassium Canrenoate, and Their Common Metabolite Canrenone"],"prefix":"10.1097","volume":"33","author":[{"given":"Andrea","family":"DeFrance","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Armbruster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Petty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelley C","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amitava","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-21-20210129","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2165\/00139709-200625040-00007","article-title":"Therapeutic drug monitoring of digoxin: impact of endogenous and exogenous digoxin-like immunoreactive substances.","volume":"25","author":"Dasgupta","year":"2006","journal-title":"Toxicol Rev"},{"key":"R2-21-20210129","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF00316635","article-title":"Difference in metabolic profile of potassium canrenoate and spironolactone in rat: mutagenic metabolites unique to potassium canrenoate.","volume":"61","author":"Cook","year":"1988","journal-title":"Arch Toxicol"},{"key":"R3-21-20210129","first-page":"787","article-title":"The effects of spironolactone and canrenone in digoxin radioimmunoassay.","volume":"9","author":"Huffman","year":"1974","journal-title":"Res Comm Chem Pathol Pharmacol"},{"key":"R4-21-20210129","first-page":"61","article-title":"The influence of intravenous canrenoate on the determination of digoxin in serum by radio and enzyme immunoassay.","volume":"17","author":"Lichey","year":"1979","journal-title":"Int J Clin Pharmacol Biopharm"},{"key":"R5-21-20210129","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/BF00540949","article-title":"The effect of renal and hepatic impairment and of spironolactone on serum digoxin assay.","volume":"34","author":"Morris","year":"1988","journal-title":"Eur J Clin Pharmacol"},{"key":"R6-21-20210129","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/00007691-198903000-00013","article-title":"Reassessment of cross-reactivity of spironolactone metabolites with four digoxin assays.","volume":"11","author":"Pleasants","year":"1989","journal-title":"Ther Drug Monit"},{"key":"R7-21-20210129","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00007691-199001000-00015","article-title":"Influence of spironolactone and its metabolite canrenone on serum digoxin assays.","volume":"12","author":"Foukaridis","year":"1990","journal-title":"Ther Drug Monit"},{"key":"R8-21-20210129","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1093\/clinchem\/35.7.1326","article-title":"An update on digoxin.","volume":"35","author":"Stone","year":"1989","journal-title":"Clin Chem"},{"key":"R9-21-20210129","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00007691-199712000-00009","article-title":"Cross-reactivity of TDX and OPUS immunoassay system for serum digoxin determination.","volume":"19","author":"Okazaki","year":"1997","journal-title":"Ther Drug Monit"},{"key":"R10-21-20210129","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/S0140-6736(99)03818-0","article-title":"Intoxication due to negative canrenone interference in digoxin monitoring [Letter].","volume":"354","author":"Steimer","year":"1999","journal-title":"Lancet"},{"key":"R11-21-20210129","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/clinchem\/48.3.507","article-title":"Digoxin assays: frequent, substantial, and potentially dangerous interference by spironolactone, canrenone and other steroids.","volume":"48","author":"Steimer","year":"2002","journal-title":"Clin Chem"},{"key":"R12-21-20210129","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0039-128X(89)90078-0","article-title":"6,7-dihydroxy-6,7-dihydrocanrenone isomers: improved synthesis and proton NMR study.","volume":"54","author":"Tal","year":"1989","journal-title":"Steroids"},{"key":"R13-21-20210129","first-page":"97","article-title":"Methods for calculating cross reactivity in immunoassays.","volume":"15","author":"Miller","year":"1992","journal-title":"J Clin Immunoassay"},{"key":"R14-21-20210129","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/j.1552-4604.1989.tb03339.x","article-title":"Spironolactone metabolism: steady state serum levels of the sulfur containing metabolites.","volume":"29","author":"Gardiner","year":"1989","journal-title":"J Clin Pharmacol"},{"key":"R15-21-20210129","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF00542109","article-title":"Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man.","volume":"25","author":"Karras","year":"1983","journal-title":"Eur J Clin Pharmacol"},{"key":"R16-21-20210129","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0022-3565(25)29552-0","article-title":"Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.","volume":"185","author":"Sadee","year":"1973","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e3181fd4c30","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T20:39:53Z","timestamp":1740688793000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201102000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3181fd4c30","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}